Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31859246

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Feb
First author
Gao JJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Feb;21(2):191-192. doi: 10.1016/S1470-2045(19)30808-3.
    note
    Source null
    related pmid
    31859247
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Mar;21(3):e130. doi: 10.1016/S1470-2045(20)30072-3.
    note
    Source null
    related pmid
    32135114
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Mar;21(3):e131. doi: 10.1016/S1470-2045(20)30095-4.
    note
    Source null
    related pmid
    32135115
    relationship
    Comment in

Authors and identifiers

  1. name
    Gao JJ
    type
    Author
  2. name
    Cheng J
    type
    Author
  3. name
    Bloomquist E
    type
    Author
  4. name
    Sanchez J
    type
    Author
  5. name
    Wedam SB
    type
    Author
  6. name
    Singh H
    type
    Author
  7. name
    Amiri-Kordestani L
    type
    Author
  8. name
    Ibrahim A
    type
    Author
  9. name
    Sridhara R
    type
    Author
  10. name
    Goldberg KB
    type
    Author
  11. name
    Theoret MR
    type
    Author
  12. name
    Kluetz PG
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gao JJ
    type
    Author
  2. name
    Cheng J
    type
    Author
  3. name
    Bloomquist E
    type
    Author
  4. name
    Sanchez J
    type
    Author
  5. name
    Wedam SB
    type
    Author
  6. name
    Singh H
    type
    Author
  7. name
    Amiri-Kordestani L
    type
    Author
  8. name
    Ibrahim A
    type
    Author
  9. name
    Sridhara R
    type
    Author
  10. name
    Goldberg KB
    type
    Author
  11. name
    Theoret MR
    type
    Author
  12. name
    Kluetz PG
    type
    Author
bibliography ids
  1. nci-bib-95145c46ede52413cbc2d932
book metadata
content sha256
d03e3848eb90eacc08182ae0a88e4caa3d6f5351cbfa2f132dbbb8c3ad1eaf70
document type
citation
dois
  1. 10.1016/S1470-2045(19)30804-6
electronic publication date
display
2019 Dec 16
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31859246
immutable id
pubmed:31859246@d03e3848eb90eacc08182ae0a88e4caa3d6f5351cbfa2f132dbbb8c3ad1eaf70
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
250-260
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Feb;21(2):191-192. doi: 10.1016/S1470-2045(19)30808-3.
    note
    Source null
    related pmid
    31859247
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Mar;21(3):e130. doi: 10.1016/S1470-2045(20)30072-3.
    note
    Source null
    related pmid
    32135114
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Mar;21(3):e131. doi: 10.1016/S1470-2045(20)30095-4.
    note
    Source null
    related pmid
    32135115
    relationship
    Comment in
outcomes validated
false
pmid
31859246
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
b1e5e3e4a49533762000c4526554cc086462a4521adb60e572163518b4f610c8
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Feb
precision
month
year
2020
publication types
  1. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31859246/
title
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.

Preserved source evidence · Not medical advice